Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185186 | 0.88 | NPC1 (0.34) | MEN1KMT2ABMP1NPC1RAB9A | |
| SCHEMBL8079493 | 0.84 | MEN1 (0.40) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL2990766 | 0.83 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9ATSHR | |
| Norleucine SCHEMBL7204454 | 0.83 | SLC1A5 (0.36) | MEN1KMT2ABMP1NPC1RAB9A | |
| SCHEMBL18304267 | 0.81 | NPC1 (0.39) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL7815464 | 0.80 | BMP1 (0.33) | MEN1KMT2ABMP1NPC1RAB9A | |
| SCHEMBL5330706 | 0.79 | NPC1 (0.36) | MEN1KMT2ABMP1NPC1RAB9A | |
| SCHEMBL7557772 | 0.79 | NPC1 (0.35) | MEN1KMT2ABMP1NPC1RAB9A | |
| SCHEMBL3386401 | 0.78 | MDM2 (0.41) | MEN1KMT2ANPC1RAB9AMDM2 | |
| SCHEMBL17500350 | 0.78 | NPC1 (0.43) | MEN1KMT2ANPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20240174727-A1 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | ELI LILLY AND COMPANY | 2024-05-30 | — | — | US | disclosed |
| WO-2024086680-A2 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-2252628-B1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | UNIVERSITÄTSSPITAL BASEL (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-9035023-B2 | Bombesin analog peptide antagonist conjugates | Piramal Imaging, SA (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | US | disclosed |
| EP-1789436-B1 | ANTIBACTERIAL PEPTIDES AND ANALOGUES THEREOF | UNIV SIENA (IT) | 2009-12-16 | — | — | EP | disclosed |
| WO-2003025001-A1 | MULTIPLE ANTIGEN PEPTIDES (MAP) AS ANTIDOTES AGAINST SNAKE NEUROTOXIN INTOXICATION | UNIVERSITA' DEGLI STUDI DI SIENA (IT) | 2003-03-27 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BRS3, VIP, GRPR | MEN1 52/4885KMT2A 3479/4885BMP1 81/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | MEN1 3617/4885KMT2A 1621/4885BMP1 1921/4885 |
| US-20240174727-A1 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | NPPA, NPR1, NPR3 | MEN1 867/4885KMT2A 4736/4885BMP1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.